Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Giftify (GIFT) announced that CardCash.com is offering consumers smart saving solutions for high-cost GLP-1 weight loss prescription ...

American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The Danish pharma giant, known for its blockbuster diabetes and weight-loss medications Ozempic and Wegovy, is on track to have its worst week on Wall Street this year. Novo Nordisk shares have ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...